Company intelligence / Profile preview

Quallent Pharmaceuticals

Parsippany, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Quallent Pharmaceuticals is a private-label distributor providing FDA-approved biosimilars, including commercial launches of high-concentration interchangeable adalimumab-ryvk (biosimilar to Humira) and ustekinumab (biosimilar to Stelara), with programs delivering substantial patient savings through copay assistance and aggressive pricing, targeting broad access in key inflammatory indications[2][4][6].

Therapeutic areas: ImmunologyRheumatologyOphthalmologyGastroenterologyDermatology
Modalities: BiologicBiosimilarSmall molecule
Industry: Biotech

Partnerships

Alvotech (manufacturing partnership for adalimumab biosimilar)[2][10]Samsung Bioepis (for ustekinumab biosimilar)[6]Teva Pharmaceuticals (U.S. commercialization agreement for biosimilars)[2][10]Boehringer Ingelheim

Beyond the preview

Go deeper on Quallent Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quallent Pharmaceuticals.

Explore the full profile